|
CONSOLIDATED STATEMENTS OF CASH FLOWS |
| |||||
|
(Unaudited) |
| |||||
|
|
Three Months Ended |
| ||||
|
|
March 29, |
|
December 28, |
|
March 30, |
|
|
|
2014 |
|
2013 |
|
2013 |
|
|
|
(in thousands) |
| ||||
|
Cash flows from operating activities: |
|
|
|
|
|
|
|
Net income |
$ 122,544 |
|
$ 44,353 |
|
$ 131,388 |
|
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
|
Stock-based compensation |
22,057 |
|
22,869 |
|
19,613 |
|
|
Depreciation and amortization |
64,665 |
|
64,404 |
|
50,391 |
|
|
Deferred taxes |
(36,482) |
|
(11,705) |
|
18,392 |
|
|
In-process research and development written-off |
2,580 |
|
- |
|
2,800 |
|
|
Loss (gain) from sale of property, plant and equipment |
818 |
|
265 |
|
(2,397) |
|
|
Tax benefit (shortfall) related to stock-based compensation |
3,204 |
|
(726) |
|
1,317 |
|
|
Impairment of long-lived assets |
- |
|
5,197 |
|
- |
|
|
Impairment of investments in privately-held companies |
3,723 |
|
- |
|
- |
|
|
Excess tax benefit from stock-based compensation |
(5,139) |
|
(2,459) |
|
(4,297) |
|
|
Loss (gain) on sale of discontinued operations |
- |
|
- |
|
(3,285) |
|
|
Changes in assets and liabilities: |
|
|
|
|
|
|
|
Accounts receivable |
(15,566) |
|
33,056 |
|
(35,501) |
|
|
Inventories |
7,717 |
|
14,030 |
|
(12,143) |
|
|
Other current assets |
7,194 |
|
30,330 |
|
(14,653) |
|
|
Accounts payable |
(4,044) |
|
(3,252) |
|
10,453 |
|
|
Income taxes payable |
14,244 |
|
19,002 |
|
9,100 |
|
|
Deferred revenue on shipments to distributors |
(1,283) |
|
(1,637) |
|
489 |
|
|
All other accrued liabilities |
25,466 |
|
20,704 |
|
40,026 |
|
|
Net cash provided by (used in) operating activities |
211,698 |
|
234,431 |
|
211,693 |
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
|
|
|
Purchase of property, plant and equipment |
(26,407) |
|
(46,133) |
|
(54,945) |
|
|
Proceeds from sales of property, plant and equipment |
618 |
|
- |
|
10,199 |
|
|
Payments in connection with business acquisition, net of cash acquired |
(5,750) |
|
(453,506) |
|
- |
|
|
Proceeds from maturity of available-for-sale securities |
- |
|
27,000 |
|
50,000 |
|
|
Net cash provided by (used in) investing activities |
(31,539) |
|
(472,639) |
|
5,254 |
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
Excess tax benefit from stock-based compensation |
5,139 |
|
2,459 |
|
4,297 |
|
|
Contingent consideration paid |
(104) |
|
(4,601) |
|
- |
|
|
Dividends paid |
(73,481) |
|
(73,324) |
|
(70,421) |
|
|
Repayment of notes payable |
(439) |
|
(1,839) |
|
(903) |
|
|
Issuance of debt |
- |
|
497,795 |
|
491,145 |
|
|
Debt issuance cost |
- |
|
(3,431) |
|
- |
|
|
Repurchase of common stock |
(51,083) |
|
(59,101) |
|
(66,330) |
|
|
Issuance of ESPP shares under employee stock purchase program |
- |
|
19,096 |
|
- |
|
|
Net issuance of restricted stock units |
(8,390) |
|
(7,106) |
|
(7,941) |
|
|
Proceeds from stock options exercised |
29,538 |
|
8,622 |
|
26,079 |
|
|
Net cash provided by (used in) financing activities |
(98,820) |
|
378,570 |
|
375,926 |
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents |
81,339 |
|
140,362 |
|
592,873 |
|
|
Cash and cash equivalents: |
|
|
|
|
|
|
|
Beginning of period |
1,149,909 |
|
1,009,547 |
|
955,107 |
|
|
End of period |
$ 1,231,248 |
|
$ 1,149,909 |
|
$ 1,547,980 |
|
|
|
|
|
|
|
|
|
|
Total cash, cash equivalents, and short-term investments |
$ 1,231,248 |
|
$ 1,149,909 |
|
$ 1,573,075 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|